Soleno Therapeutics Inc - Asset Resilience Ratio
Soleno Therapeutics Inc (SLNO) has an Asset Resilience Ratio of 20.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Soleno Therapeutics Inc's Asset Resilience Ratio has changed over time. Check SLNO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Soleno Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Soleno Therapeutics Inc (SLNO) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $122.57 Million | 20.15% |
| Total Liquid Assets | $122.57 Million | 20.15% |
Asset Resilience Insights
- Good Liquidity Position: Soleno Therapeutics Inc maintains a healthy 20.15% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Soleno Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Soleno Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Soleno Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.74% | $235.37 Million | $563.83 Million | -19.74pp |
| 2024-12-31 | 61.49% | $203.51 Million | $330.97 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $180.69 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $38.17 Million | -- |
| 2018-12-31 | 2.27% | $978.00K | $43.15 Million | +2.18pp |
| 2017-12-31 | 0.09% | $35.00K | $39.02 Million | -0.54pp |
| 2016-12-31 | 0.63% | $35.00K | $5.56 Million | +0.20pp |
| 2015-12-31 | 0.43% | $35.00K | $8.20 Million | +0.19pp |
| 2014-12-31 | 0.24% | $20.00K | $8.40 Million | -1.02pp |
| 2013-12-31 | 1.26% | $20.00K | $1.59 Million | +0.46pp |
| 2012-12-31 | 0.80% | $20.00K | $2.51 Million | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more